ArticleJournal of nanobiotechnology2026
H
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtherosclerosis is a chronic inflammatory disease characterized by pathological vascular alterations, including endothelial cell dysfunction and apoptosis, macrophage infiltration, lipid deposition within the intima. Due to this complex pathophysiology, current therapeutic approaches lack effective systems for the precise delivery of antioxidant and anti-inflammatory agents to the affected sites.
resultsHerein we developed a reactive oxygen species (ROS)-responsive M2 macrophage membrane-camouflaged biomimetic drug delivery nanosystem (MM@TIIA-NPs) to dual-targeted delivery tanshinone IIA for enhanced anti-atherosclerosis. The dual-targeting capability arises from the combination of M2 macrophage membrane-mediated biological targeting, which promotes preferential accumulation at inflammatory atherosclerotic plaques while reducing reticuloendothelial system clearance, and H
conclusionIn conclusion, MM@TIIA-NPs represent a promising therapeutic strategy for atherosclerosis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.